Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
Backed by Novartis’ venture arm, El Lilly and CRISPR Therapeutics, Seawolf is advancing its nonviral DNA delivery platform while inking a pact with Sanofi.
Backed by Novartis’ venture arm, El Lilly and CRISPR Therapeutics, Seawolf is advancing its nonviral DNA delivery platform while inking a pact with Sanofi.
comments(0)
5-min edit window · permanent after that